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Abstract 
     Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) is chronic progressive myelopathy characterized by 
bilateral pyramidal tracts involvement with sphincteric disturbances. HTLV-I infects 
approximately 10-20 million people worldwide. There are large endemic areas in 
southern Japan, the Caribbean, Central and South America, the Middle East, Melanesia, 
and equatorial regions of Africa. Since the primary neuropathological feature of 
HAM/TSP is chronic inflammation caused by HTLV-I infection in the spinal cord, 
various treatments focusing on immunomodulatory or anti-viral effects were performed 
for HAM/TSP patients until now. However, there are still many of problems, such as 
insufficient effects, side effects and expensive costs in long-term treatments, etc., in 
these treatments. Therefore, an ideal therapeutic strategy against HAM/TSP is still not 
established yet. Although only a small proportion of HTLV-I-infected individuals 
develops HAM/TSP, neurological symptoms are certainly progressive once myelopathy 
develops, leading to deterioration of the quality of life. Therefore, we now need the 
therapeutic regimens to protect the development, or be able to commence the treatments 
as soon as possible after the development safely and inexpensively even in long-term 
course or lifelong course of treatment. As HTLV-I-infected CD4+ T cells are the first 
responders in the immunopathogenesis of HAM/TSP, the ideal treatment is the 
elimination of HTLV-I-infected cells from the peripheral blood. In this article, We will 
review the therapeutic strategies against HAM/TSP up to now and will introduce our 
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new therapeutic approach focusing on the targeting of HTLV-I-infected cells in 
HAM/TSP patients.   
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Introduction 
     Human T lymphotropic virus type I (HTLV-I) is a member of the exogeneous 
human retroviruses and the causative agent for both adult T cell leukemia (ATL) and 
HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [1, 2]. Since 
the discovery of HAM/TSP, it was revealed that HTLV-I has the potentials to not only 
act as one of the oncoviruses but also cause a chronic inflammation by the immunologic 
activation. However, the exact mechanisms underlying the entirely different clinical 
conditions caused by HTLV-I, such as aggressive lymphoproliferative malignancy and 
chronic inflammation, are still unknown. HTLV-I infects approximately 10-20 million 
people worldwide [3]. Although there are large endemic areas in southern Japan, the 
Caribbean, Central and South America, the Middle East, Melanesia, and equatorial 
regions of Africa [4], it is still not clear why only a small proportion of HTLV-I-infected 
individuals develops either of these HTLV-I-associated diseases. 
     HAM/TSP is chronic progressive myelopathy characterized by bilateral 
pyramidal tracts involvement, clinically presented as spastic paraparesis, with 
sphincteric disturbances [5]. The primary pathological feature of HAM/TSP is chronic 
myelitis formed by chronic inflammation in the spinal cord, mainly the lower thoracic 
cord, characterized by perivascular cuffing and parenchymal infiltration of mononuclear 
cells [6]. Although the bystander mechanisms, such as the destruction of the 
surrounding tissues by the interaction between HTLV-I-infected CD4+ T cells and 
HTLV-I-specific CD8+ cytotoxic T cells (CTL),are probably critical as the cause of 
chronic inflammation in the spinal cord [7, 8] (Fig. (1)), the exact molecular 
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mechanisms of the development of HAM/TSP still remain unresolved. However, it is 
well known that HTLV-I proviral load in the peripheral blood is significantly higher in 
HAM/TSP patients than HTLV-I asymptomatic carriers [9, 10]. On the other hand, 
numerous immunological dysregulations mostly mediated by HTLV-I tax expression are 
detected in the peripheral blood of HAM/TSP patients [11, 12]. Therefore, it is strongly 
supposed that the increase of HTLV-I-infected cells possessing immune-activated status, 
such as Th1 activation, is involved in the immunopathogenesis of HAM/TSP [13] 
although it is still controversial whether or not HTLV-I exists in the neuronal 
components of the central nervous system. 
     When considering the therapeutic strategies in HAM/TSP, they are divided to two 
ways of the direction as shown in Table 1 and Fig. (1) although both ways connect to 
each other in some part; 1) immunomodulation therapy, mainly directed to 
anti-inflammatory effects, 2) anti-viral therapy. Once the myelopathy developed, the 
neurological symptoms are certainly progressive, leading to the deterioration of the 
qulity of the life. Therefore, we now need the therapeutic regimens to protect the 
development, or be able to commence the treatments as soon as possible after the 
development safely and inexpensively even in long-term or lifelong course of treatment. 
A number of therapeutic approaches for HAM/TSP were carried out until now as shown 
in Table 2 although almost trials were performed under an open, nonrandomized, 
uncontrolled studies. Of them, immunomodulation therapies for the suppression of 
chronic inflammatory status based on immune-activated status as mentioned above were 
mainly performed for HAM/TSP patients. Indeed, as it is conceivable that the 
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immune-activated status in the peripheral blood involved in the process of chronic 
inflammation of the spinal cord is one of the targets for the treatments, almost all 
treatments produced the good results in their own ways. However, since 
HTLV-I-infected CD4+ T cells are the first responders in the immunopathogenesis of 
HAM/TSP as mentioned above, the primary target for HAM/TSP treatment is 
HTLV-I-infected cells themselves of the peripheral blood. Therefore, we should focus 
on the targeting of HTLV-I-infected cells themselves or the suppression of HTLV-I 
expression and/or replication in the peripheral blood. 
     In this review, we will refer to the therapeutic strategies, such as the therapies 
focusing on immunomodulatory effects or anti-viral effects, against HAM/TSP up to 
now. In addition, we will introduce our new therapeutic approach focusing on the 
targeting of HTLV-I-infected cells in HAM/TSP patients.   
  
1) The therapies focusing on immunomodulatory effects 
     This strategy is mainly directed to anti-inflammatory effects as shown in Table 1 
and Fig. (1), such as 1) the suppression of immune activation, particularly for activated 
HTLV-I-infected cells, 2) the inhibition of the transmigration of these cells to the spinal 
cord, 3) the reduction of chronic inflammation in the spinal cord, through the 
down-regulation of inflammatory cytokines and/or adhesion molecules expression, etc.. 
The regimens, of course, exhibit the effects also for the activated HTLV-I-non-infected 
cells, which are subsequently induced by the activation of HTLV-I-infected cells. 
a) Corticosteroid hormone 
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     As well known, this reagent has been shown to be a useful in various 
inflammatory or autoimmune diseases. Although high-doses of methylprednisolone are 
sometimes given intravenously, oral administration of prednisolone (PSL) is most 
popular treatment against HAM/TSP in Japan. Nakagawa et al. recommended that 1 to 2 
mg/kg of PSL are given every day or every other day for 1 to 2 months and the dose of 
PSL, thereafter, is tapered off 5 to 10 mg every other day or is terminated at 6 to 12 
months after commencement [14]. They mentioned that 107 (81.7%) of 131 HAM/TSP 
patients showed improvement of motor function in this therapy. On the other hand, there 
are some reports that corticosteroid therapy was non-efficacious or the effect of this 
treatment was transient [15, 16]. Therefore, the efficacy of this treatment for HAM/TSP 
patients is still controversial although this treatment might show the efficacy in a 
short-term trial. In addition, there are many adverse events , such as infection, 
osteoporosis, gastroduodenal ulcer, glucose intolerance, hypertension, and myopathy etc. 
in a long-term administration of corticosteroid. However, the fact that HTLV-I proviral 
load in the peripheral blood of HAM/TSP patients was significantly decreased in PSL 
treatment during 5 years might be noteworthy [17] although its mechanism is unclear. 
 
b) Blood purification 
     There are two methods, such as plasmapheresis and lymphocytapheresis. We 
previously treated 18 HAM/TSP patients with plasmapheresis using AP-05H plasma 
separator or IM-T350 immunoadsorbent column (Asahi Medical Co, Tokyo, Japan) [18]. 
In 11 of 18 HAM/TSP patients (61.1%) motor, sensory, and/or shincteric disturbance 
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improved with plasmapheresis (4 to 6 sessions in 2 weeks). Although no adverse events 
were observed, the effects were transient as maintained only for 2 to 4 weeks. It is 
supposed that the efficacy of this treatment is based on the elimination of some humoral 
factors involved in the damage of nervous tissues, such as inflammatory cytokines. 
However, the exact mechanisms how plasmapheresis treatment induces clinical 
improvements in HAM/TSP patients are still unclear.  
 
c) Pentoxifylline 
Pentoxifylline (PTX) (3,7-dimethyl-1-(5-oxohexyl) xanthine), an inhibitor of 
phosphodiesterase, is a methylxanthine derivative used in the treatment of vascular 
diseases [19]. In addition to rheological effects, it is known that PTX has 
anti-inflammatory or immunomodulatory activity through the increase of intracellular 
cAMP, such as the suppression of inflammatory cytokines expression including tumor 
necrosis factor-, interferon- and granulocyte-monocyte colony stimulating factor and 
the down-regulation of adhesion molecules expression [20, 21]. We previously treated 
15 HAM/TSP patients by oral administration of 300 mg/day of PTX for 4 weeks [22]. 
In 13 of 15 patients, motor disability, especially spasticity, improved concomitant with 
the suppression of spontaneous peripheral blood lymphocyte (PBL) proliferation, which 
is one of the major immunological abnormalities observed in vitro in patients with 
HAM/TSP [23]. No adverse events were observed. The fact that the clinical efficacy 
was correlated with the elevation of serum Th2 cytokine levels in PTX treatment 
suggests that PTX has the potentials to regulate the balance of Th1/Th2 activity [24]. 
CNSA-MC-183125, Nakamura, et al., page 9
Thus, although the exact mechanisms with regard to the efficacy of PTX treatment is 
still obscure, the correction of the imbalance of Th1/Th2 activity in HAM/TSP patients 
[25] concomitant with the down-regulation of adhesion molecules, such as integrins 
expression, might be involved in the efficacy as a one of the mechanisms.  
 
d) Heparin 
The main regions in the pathological changes of HAM/TSP are the lower thoracic 
cord in the spinal cord as mentioned above [6]. These regions are anatomically 
watershed zones of the spinal cord [26], where the stagnant lymphocytes could easily 
transmigrate to the the tissues and evoke the immune reactions because of decreased 
blood flow. Indeed, the efficacies of heparin treatment based on the inhibition of 
lymphocytes trafficking to the tissues were also reported in another inflammatory 
diseases, such as multiple sclerosis and experimental autoimmune encephalomyelitis 
[27, 28]. Therefore, heparin was administered to HAM/TSP patients with the 
expectation of the clinical improvement by the inhibition of the transmigration of 
activated T cells to the lower thoracic cord in the spinal cord due to the improvement of 
the microcirculation. We treated 10 HAM/TSP patients by intravenous administration of 
5000 - 10,000 units/day of heparin for 9 - 93 days [29]. In 7 patients, motor dysfunction 
improved substantially and the effect continued for more than a month after the 
discontinuation of therapy. No adverse events were observed. Most striking change of 
the immunological markers in the peripheral blood during treatment was the significant 
decrease of spontaneous PBL proliferation in vitro. Although the exact mechanisms of 
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this phenomenon are unclear, it is supposed that heparin can induce not only the 
amelioration of the microcirculation but also the down-regulation of immunological 
activations based on HTLV-I infection. Considering the efficacy of heparin treatment 
together with PTX treatment, they seem to originate in the inhibition of the 
transmigration of HTLV-I-infected cells to the spinal cord based on immunomodulatory 
effects with rheological effects. 
    
e) High-dose intravenous gammaglobulin 
     High-dose intravenous gammaglobulin (IVIG) is used in the treatment in various 
inflammatory or immune-mediated diseases [30]. Kuroda et al. reported that 10 of 14 
HAM/TSP patients had presented the improvement of motor disability within 7 days of 
the commencement by administration of 10g/day or 400 mg/kg/day of gammaglobulin 
for 5 consecutive day and the effects were sustained for more than 3 weeks in some 
patients [31]. Although the exact mechanisms how IVIG exhibits the efficacy, even in 
another immune-mediated diseases, are still unclear [30], they mentioned the possibility 
of the suppression of perivascular inflammation from the fact that the clinical 
improvement was preferentially observed in patients with high anti-HTLV-I antibodies 
titer in cerebral spinal fluid (CSF), a high CSF IgG level and a severe white-matter 
lesion on brain MRI.  
 
f) Intermittent high-dose vitamin C 
     Kataoka et al. reported the therapeutic efficacy of intermittent high-dose vitamine 
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C. They treated 7 HAM/TSP patients by oral administration of 35-40 mg/kg/day of 
vitamin C in following manner, 3 to 5 successive days followed by a 2-day withdrawal 
period, for a mean period of 9.7 months [32]. All of patients presented the improvement 
of motor function with the decrement of serum level of immunosuppressive acidic 
protein, suggesting the suppression of macrophage activation. However, the 
mechanisms how the down-regulation of activated macrophages are involved in the 
efficacy of this treatment are not unclear. 
 
g) Fosfomycin and Erythromycin 
     Of 14 HAM/TSP patients treated with intravenous administration of 2 g/day of 
fosfomycin for 2 weeks followed by oral administration of 2 g/day of fosfomycin for 2 
weeks, 11 patients showed the improvement of motor function [14]. Of 25 HAM/TSP 
patients treated with oral administration of 600 mg/day of erythromycin for 1 to 3 
months, 12 patients showed moderate improvements in their motor function [33]. Since 
these regimens have not only anti-bacterial effects but also immunomodulatory 
functions [34, 35], the efficacy by these regimens is supposed to be based on the 
down-regulation of inflammatory cytokines or chemokines expression.    
 
h) Fermented milk drink 
     Lactobacillus casei strain Shirota (LcS) is one of probiotic agents, which have 
immnomodulatory functions through the interactions with the gastrointestinal mucosal 
immune system [36]. Matsuzaki et al. reported that oral administration of 4 x 1010 
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viable LcS, twice a day for 4 weeks induced the improvement of motor dysfunction, 
particularly decrease of spasticity, and of urinary symptoms in all of 10 HAM/TSP 
patients treated [37]. In addition, the increase of NK cell activity, which was generally 
decreased in HAM/TSP patients [38, 39], in the peripheral blood was observed in LcS 
treatment. However, there were no significant changes of not only lymphocytes surface 
markers but also HTLV-I proviral load in the peripheral blood in the course of LcS 
treatment. Although the mechanisms how the up-regulation of NK cell activity without 
the decrement of HTLV-I proviral load in the peripheral blood are involved in clinical 
improvement is unclear, the benefit which can use safely as the supplement during a 
long-term might be valuable for the treatment against HAM/TSP patients.  
 
2) The therapies focusing on anti-viral effects 
This strategy is mainly directed to anti-viral effects as shown in Table 1and Fig. 
(1), such as 1) the suppression of HTLV-I expression and/or replication, 2) the inhibition 
of the proliferation of HTLV-I-infected cells, 3) the elimination of HTLV-I-infected 
cells. 
a) Interferon-and - 
     Interferon (IFN)- and IFN-, which are type I IFNs, have a variety of biological 
actions including not only anti-viral effects but also cell growth regulation and 
modulation of the cellular immune response [40, 41, 42]. Therefore, treatment with 
these regimens might be suitable for HAM/TSP because it can target on the 
immunological dysregulation based on high HTLV-I proviral load in the peripheral 
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blood of HAM/TSP. 
     In various treatments against HAM/TSP, only IFN-has been proved to be 
effective in a multicenter, randomized, double-blind, and controlled trial [43] and has 
been approved as the therapeutic agent against HAM/TSP by the Ministry of Health, 
Labor and Welfare in Japan. In controlled tial of IFN- treatment against HAM/TSP as 
mentioned above, 48 HAM/TSP patients were divided to three groups treated with 0.3 
million international units (MU) of natural IFN- (human lymphoblastoid interferon 
(HLBI, Sumiferon) (Sumitomo Pharmaceutical Co., Osaka, Japan), 1.0 MU, and 3.0 
MU by intramuscular injection, respectively, daily for 4 weeks. In about 70 % of 
HAM/TSP patients treated with 3.0 MU, motor dysfunction, even urinary disturbances 
in some cases, improved in significant therapeutic response and its effectiveness 
continued for 4 weeks after completion of therapy without serious adverse effects. The 
therapeutic response in the 3.0-MU group was significantly higher than in the 0.3-MU 
group. We, previously, had also demonstrated a similar efficacy of HLBI treatment 
against 17 HAM/TSP patients in open trial [44]. In this trial, most striking change of the 
immunological markers in the peripheral blood was the significant decrease of 
spontaneous PBL proliferation in vitro leading to the recovery of the response to lectin, 
such as phytohemoagglutinin. Although spontaneous PBL proliferation is one of the 
major immunological abnormalities observed in vitro in patients with HAM/TSP as 
mentioned above [23], the exact mechanisms of it are still unclear. However, this 
phenomenon is thought to consist of the proliferation of HTLV-I-infected CD4+ T cells 
and the expansion of HTLV-I specific CD8+ CTL against virus-expressing cells 
CNSA-MC-183125, Nakamura, et al., page 14
concomitant with the involvement of the aberrant signalings of both Interleukin-2 (IL-2) 
and IL-15 [45, 46]. It was reported that HTLV-I proviral load and HTLV-I tax mRNA 
expression correlate the frequency of HTLV-I tax specific CD8+ CTL in the peripheral 
blood of HAM/TSP patients [47, 48]. Therefore, IFN- treatment might induce the 
reduction of HTLV-I proviral load or HTLV-I tax mRNA expression in the peripheral 
blood of HAM/TSP patients. Indeed, Saito et al. recently, reported that HTLV-I proviral 
loads in the peripheral blood were significantly decreased, concomitant with the 
reduction of memory T cells in CD8high+ T cells, after IFN- treatment [49]. In addition, 
CXCR3+ T cells (Th1 cells) were also significantly decreased by this treatment. Thus, 
IFN- treatment seems to also induce the correction of Th1/Th2 imbalance, which 
deviates toward Th1 in HAM/TSP [25]. Indeed, another reports also demonstrated that 
both the percentage of CCR5+ cells (Th1 cells) in CD4+ T cells and the ratio of 
intracellular IFN-+/IL-4+ T cell in the peripheral blood were significantly decreased by 
IFN- treatment [50].       
On the other hand, the efficacy of IFN-, which is another type I IFN, treatment 
against HAM/TSP was also reported [51]. Twelve patients with HAM/TSP were treated 
with escalating doses of IFN-1a, which has already been approved as the treatment 
against multiple sclerosis [52], over the course of a relatively long-term, 28 weeks. This 
treatment induced the improvement of motor dysfunction with the reduction of both 
HTLV-I tax mRNA load and the frequency of HTLV-I-specific CD8+ CTL in the 
peripheral blood. Although up-regulated expression of HTLV-I tax itself in 
HTLV-I-infected cells might be one of important factors for the development of 
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HAM/TSP [48, 53], IFN-1a treatment might be able to target this point. In addition, 
the reduction of spontaneous PBL proliferation was also observed as same as it in 
IFN- treatment. However, HTLV-I proviral load in the peripheral blood remained 
unchanged. With regard to the change of HTLV-I proviral load, the reasons of the 
discrepancy between IFN- and IFN-1a treatment are unclear. However, although 
IFN- treatment as mentioned above induced the significant reduction of HTLV-I 
proviral load in total study population, HTLV-I proviral load was rather increased in 
about 30 % out of total study population [49], suggesting that anti-viral effects of IFN- 
are different among each individual.   
High HTLV-I proviral load in the peripheral blood is the most important 
prerequisite in the development of HAM/TSP [9, 10]. At present time, the increased 
proliferation of HTLV-I-infected cells is thought to play an important role mainly in the 
maintenance of high HTLV-I proviral load in the peripheral blood [12, 54, 55]. Either 
IFN-or IFN- treatment does not seem to target this point. However, it is certain that 
these regimens have somewhat anti-viral activity although its mechanism is obscure. In 
addition, these regimens also have the activities to correct various immunological 
dysregulations, such as the imbalance of Th1/Th2 status, in the peripheral blood of 
HAM/TSP patients. Therefore, these treatments have considerable benefits on 
therapeutic strategies for HAM/TSP. However, whether these treatments are tolerable as 
a long-term or lifelong treatment or not is uncertain.  
 
b) Reverse transcriptase inhibitors 
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Some nucleoside analogues have been shown to block HTLV-I replication by 
inhibition of reverse transcriptase (RT). Zidovudine (azidothymidine, AZT), which is 
the thymidine analogue, can inhibit HTLV-I replication in vitro although its inhibitory 
dose for HTLV-I is higher than for human immunodeficiency virus [56]. Zidovudine 
treatment against 5 HAM/TSP patients during 6 months did not induce the clinical 
benefits at a first study [57]. However, zidovudine, with higher dose than it in a first 
study, treatment against 10 HAM/TSP patients for 24 weeks induced the clinical 
benefits in some patients [58]. However, these studies did not refer to the change of 
HTLV-I proviral load in each treatment. On the other hand, the clinical trial against 
HAM/TSP patients with lamivudine, which is the cytosine analogue, was also reported 
[59]. Although lamivudine treatment against 5 HAM/TSP patients during about 10 
months did not induce any symptomatic improvements except one patient, who is a case 
with recent-onset HAM/TSP, the significant reduction of HTLV-I proviral load in the 
peripheral blood was observed in all 5 HAM/TSP patients. In addition, the reduction of 
viral load was associated with the decrease of the frequency of HTLV-I tax specific CTL 
in one patient who had the clinical efficacy. Thus, RT inhibitors seemed to have some 
clinical benefits with HTLV-I targeting in the treatment against HAM/TSP.  
However, unfortunately, the result of recent clinical trial with combination 
therapy by zidovudine and lamivudine in a randomized, double blind, placebo 
controlled study made RT inhibitors pessimistic for the regimen for HTLV-I targeting as 
the treatment against HAM/TSP [60]. Same group, which reported the efficacy of 
lamivudine treatment against HAM/TSP, has conducted a controlled study of 6 months 
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by combination therapy with these two RT inhibitors for 16 HAM/TSP patients. As far 
as they compared the clinical effects including motor disbility score, gait, and bladder 
function, etc., and the changes of laboratory markers in the peripheral blood including 
HTLV-I proviral load and T cell subpopulation between each group treated by combined 
therapy or placebo therapy, no significant changes were seen between two arms 
although the treatment was well tolerated with no unexpected side effects. This finding 
strongly suggests that both RT inhibitors have no activities to reduce HTLV-I proviral 
load, at least, in vivo in HAM/TSP patients. In addition, the reasons of the discrepancy 
of the results between two studies conducted by same group are unclear. However, if the 
increased proliferation of HTLV-I-infected cells, rather than new infection through 
cell-to-cell spread, plays an important role mainly in the maintenance of high HTLV-I 
proviral load in the peripheral blood of HAM/TSP patients [12, 54, 55], the inefficacy of 
the treatment with RT inhibitors might be reasonable. 
 
c) Humanized anti-Tac 
     It is well known that interleukin-2 (IL-2) and IL-2 receptor  (IL-2R) are 
induced by HTLV-I tax transactivation in HTLV-I-infected cells [61, 62]. This 
dysregulation of cellular genes expression by HTLV-I tax initiates a process of T cell 
activation and proliferation by autocrine or paracrine loop. Therefore, the blockade of 
IL-2/IL-2R system might lead to the direction toward the decrease of HTLV-I-infected 
cells in vivo through apoptosis of HTLV-I-infected cells by IL-2 deprivation. The 
efficacies of humanized anti-Tac antibody (daclizumab), which is the humanized form 
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of monoclonal antibody against IL-2Rand blocks the interaction of IL-2 with IL-2R, 
treatments were demonstrated in several immune-mediated like diseases, such as renal 
allograft rejection, noninfectious uveitis, multiple sclerosis, pure red cell aplasia, 
aplastic anemia, and psoriasis, and T-cell malignancy [63]. 
     Nine patients with HAM/TSP were treated with administration of five doses  
(1 mg/kg) of humanized anti-Tac antibody at weeks 0, 2, 6, 10, 14 [64]. This treatment 
induced mild improvement of motor disability score in only 3 HAM/TSP patients 
without serious adverse effects. On the other hand, immunological studies, as expected, 
revealed a selective down-regulation in the number of circulating activated T cells 
expressing IL-2R receptor and a decrease of spontaneous PBL proliferation ex vivo. 
Furthermore, as most striking finding, HTLV-I proviral load in the peripheral blood was 
reduced an average of 52 % after this treatment. These findings suggest that humanized 
anti-Tac treatment have the potential to selectively remove HTLV-I-infected cells 
expressing IL-2R from the peripheral blood of HAM/TSP patients. 
 
d) Histone deacetylase enzyme inhibitor 
Histone deacetylase enzyme (HDAC) inhibitor has lately attracted considerable 
attention as the therapeutic regimens against various diseases such as malignancies, and 
neurodegenerative diseases etc. [65, 66]. Although acetylated histones are associated 
with trascriptionally active chromatin and deacetylated histones with inactive chromatin, 
chromatin acetylation is regulated by the balance between histone acetyltransferases and 
histone deacetylases (HDACs) as epigenetic control under physiological conditions. 
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Histone acetylation plays an important role also in the regulation of HTLV-I gene 
expression [67, 68]. Therefore, Inhibition of HDACs activities leads into histone 
hyperacetylation followed by increases in HTLV-I gene expression.  
As mentioned above, the relationship between HTLV-I proviral load and/or 
expression and the host immune system, such as HTLV-I specific CTL, is at equilibrium 
in the peripheral blood [12]. Therefore, if HTLV-I proviral load is increased based on 
up-regulation of HTLV-I expression, e.g. in cells infected with latent or silent form , 
HTLV-specific CTL are more activated and number of HTLV-I-infected cells might be 
reduced in the peripheral blood. That is, the tilting of host-pathogen balance might lead 
to the elimination of HTLV-I-infected cells from HAM/TSP patients. Based on this new 
concept such as “gene activation therapy”, very recently, clinical trial by oral 
administration of 20 mg/kg/day valproate (VPA), which is one of HDAC inhibitors, 
during 3 months was performed in 16 HAM/TSP patients [69]. Although HTLV-I 
proviral loads in the peripheral blood were transiently increased in early stages after 
administration as expected, they significantly decreased in all patients by 2.3- to 
89.3-fold (mean; 24-fold) at the end point. Although authors did not describe the 
changes of clinical status in detail, they mentioned that VPA treatment induced the 
reduction of spasticity in all patients. This result is very intriguing because there are no 
reports such a significant drop of HTLV-I proviral load in the treatments against 
HAM/TSP until now.  
However, there is one report that HDAC inhibitors including VPA, sodium 
butyrate, and trichostatin A, unexpectedly, decrease the activity of HTLV-I specific CTL 
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against the increased HTLV-I expression in HTLV-I-infected cell ex vivo [70]. This 
finding suggests that HDAC inhibitors reduce the efficiency of CTL surveillance of 
HTLV-I and is contrary to the concept leading to the treatment with HDAC inhibitors as 
mentioned above. Indeed, VPA induced apoptosis in not only CD4+ but also CD8+ cells 
at relatively high frequency in short-term in vitro treatment [69]. Then, authors 
recommend caution in the use of HDAC inhibitors in nonmalignant cases of HTLV-I 
infection such as HAM/TSP.  
Overall, anyway, VPA is the anti-epileptic drug which has the good safety profiles 
as long-term therapy and is easily available. Since this drug might be expected as one of 
new anti-HTLV-I agents, we now need to perform the case controlled study by VPA 
treatment against HAM/TSP patients.  
 
3) New therapeutic approach focusing on anti-viral effect 
     As another therapeutic strategy for the elimination of HTLV-I-infected cells, we 
can focus on the targeting of HTLV-I-infected cells themselves from the peripheral 
blood. If HTLV-I-infected cells is selectively removed, for example-by apoptosis, from 
the peripheral blood, its strategy must become one of the ideal therapeutic tools against 
HAM/TSP patients. With this regard, the strategy requires the regimen, which is well 
tolerated, additionally inexpensive, even in long-term treatment.  
Allicin (diallyl thiosulfinate), which is one of natural organosulfur compounds 
derived from garlic (Allium sativum), has diverse biological activities, such as 
anticarcinogenic activity, antibacterial activity, antifungal activity, etc. [71, 72]. 
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Although the exact mechanisms how cytotoxic effects described above are induced by 
organosulfur compounds, such as allicin, are still obscure, a disulfide moiety in their 
structures seems to have an important role for the trigger of cell death [73]. The 
disruption of the intracellular redox system induced by the chemical reaction of a 
disulfide moiety with thiol-containing intracellular molecules, such as thioredoxin (Trx), 
Trx reductase, and glutathione (GSH), etc., might be involved in cytotoxic effects [71].  
However, allicin is very unstable compound as reported that this compound rapidly 
disappears after the injection into the blood [74, 75]. Therefore, it is difficult to use this 
compound in the therapeutic trial against HAM/TSP patients. Prosultiamine 
(N-[(4-amino-2-methyl-5-pyrimidinyl) methyl]- 
N-[4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl]-formamide) (Alinamin®), which is 
the product of Takeda Pharma. Co. Inc., Osaka, Japan, is a homologue of allithiamine 
originally synthesized by thiol type vitamin B1 and allicin (Fig. (2)) [76]. For the 
stability in the blood and the efficient access of vitamin B1 to the tissues, prosultiamine 
was developed after allyl disulfide derived from allicin was substituted to propyl 
disulfide in the structure of allithiamine (Fig. (2)) [77]. Thus, Prosultiamine has a 
disulfide moiety in its structure as same as allicin (Fig. (2)). Therefore, it is expected 
that prosultiamine has the same activity as allicin. Importantly, Prosultiamine is 
pharmacologically stable and is very frequently available as the regimen of vitamin B1 
deficiency with the safety in Japan. Therefore, this drug has the potential to be able to 
immediately conduct the clinical trial against HAM/TSP patients. We showed the 
structure of allicin and the generation of prosultiamine (Fig. (2)).  
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a) Prosultiamine has the cytotoxic activity against HTLV-I-infected T cell lines 
derived from HAM/TSP patients as same as allicin. 
It is revealed, by MTS assay 
((3-[4,5-dimethylthiazol-2-yl-5]-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H 
tetrazolium) nonradioactive cell proliferation assay), that cell viability of two 
HTLV-I-infected T cell lines derived from HAM/TSP patients (HCT-1 and HCT-4) 
decreased by allicin treatment in dose-dependent manner (Fig. (3a)). Prosultiamine 
(kindly provided by Takeda Pharma Co. Inc., Osaka, Japan) treatment against these cell 
lines also caused the similar effect to allicin treatment as expected (Fig. (3b)). As shown 
in Fig. (3ab), HTLV-I-infected T cell lines were more sensitive for the treatment with 
each compound than HTLV-I-non-infected T cell line, Jurkat cell line. These results 
suggest that the cytotoxic effect against HTLV-I-infected T cell lines is based on the 
disulfide moiety as the common structure in these compounds (Fig. (2)). 
b) The cytotoxic effect of prosultiamine is based on caspase-dependent apoptosis. 
     As shown in Fig. (4a), prosultiamine treatment against HCT-1 induced the loss of 
mitochondrial membrane potential with the appearance of annexin V-positive cells, 
suggesting that the cytotoxicity by prosultiamine was based on the cell death induced by 
apoptosis through the mitochondrial pathway. Indeed, as shown in Fig. (4b), the loss of 
mitochondrial membrane potential was recovered in z-VAD-fmk, which is pan-caspase 
inhibitor, -pretreated HCT-1. In addition, immunoblot analysis revealed that the 
treatment with prosultiamine resulted in the proteolytic cleavage of caspase 3, which is 
the effector molecule in the final process of apoptosis (Fig. (4c)). Overall, these results 
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suggested that prosultiamine can induce caspase-dependent apoptosis through the 
mitochondrial pathway for HTLV-I-infected T cells. 
c) Involvement of activation of apoptosis signal-regulating kinase (ASK) 1 
signaling in the induction of caspase-dependent apoptosis in 
prosultiamine-treated HTLV-I-infected cells. 
As mentioned above, Trx plays an important role in the cellular reducing system, 
interacting with GSH [78]. Although Trx is ubiqutaously expressed in many cell types 
of mammalians [79], human Trx is a homologue of adult T cell leukemia-derived factor 
(ADF), which was originally defined as an IL-2 receptor a-chain inducer produced by 
HTLV-I-transformed T cells [80, 81]. Trx is a small protein (12 kDa) with two 
redox-active cysteine residues in an active center (-Cys-Gly-Pro-Cys-) and operates 
together with NADPH and Trx reductase as a protein disulfide-reducing system [79, 82]. 
Apoptosis signal-regulating kinase (ASK) 1 is a mitogen-activated protein (MAP) 
kinase kinase kinase, which is located in the upstream of p38 MAP kinase (p38 MAPK) 
and c-Jun N-terminal kinase (JNK) leading to cytokine- and stress-induced apoptosis 
[83, 84]. Trx is a redox-sensitive physiological inhibitor of ASK1 activity [85]. Reduced 
form of Trx binds to ASK1 and inhibits kinase activity of ASK1. However, upon the 
change to oxidized form of Trx such as formation of disulfides through the oxidation of 
cysteine residues, ASK1 dissociates from Trx and a free ASK1 is autophosphorylated in 
Threonine residue, subsequently activates the cascade of apoptosis signaling [86]. 
Therefore, prosultiamine might have the potentials to oxidize Trx in the interaction 
between Trx/Trx reductase system and a disulfide moiety and induce ASK1 activation 
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leading to the induction of apoptosis of HTLV-I-infected cells. We showed the 
hypothetical pathway in allicin or prosultiamine-induced apoptosis of HTLV-I-infected 
cells (Fig. (5)). 
     As shown in Fig. (6), immunoblot analysis revealed that ASK1 is activated within 
a short period after prosultiamine treatment in HCT-1. It is reported that activation of 
p38 MAPK, which is located in the downstream of ASK1 signaling, connects to the 
mitochondrial apoptotic pathway through caspase 8 [87]. Therefore, as mentioned 
above, the fact that the loss of mitochondrial membrane potential was recovered in 
z-VAD-fmk-pretreated HCT-1 suggests that the activation of ASK1 signaling is 
involved in apoptosis of HTLV-I-infected cells by the treatment with prosultiamine. 
d) The decrease of numbers of HTLV-I provirus in the peripheral blood CD4+ T 
cells of HAM/TSP patients by the in vitro treatment with prosultiamine and 
clinical trial with prosultiamine against HAM/TSP patients. 
In next, we studied whether prosultiamine in vitro treatment can selectively target 
HTLV-I-infected cells of peripheral blood CD4+ T cells of HAM/TSP patients or not. 
After the peripheral blood CD4+ T cells of HAM/TSP patients were cultured in the 
presence of 5 M prosultiamine or vehicle for 48 hr, total cellular DNA samples 
prepared from the viable cells were subjected to the measurement of HTLV-I proviral 
copies by quantitative PCR analysis. As shown in Fig. (7a), prosultiamine in vitro 
treatment against the peripheral blood CD4+ T cells of 7 HAM/TSP patients induced the 
decrease of numbers of HTLV-I proviral copies, ranged from 29.9 - 80.2% (mean; 
60.7%), compared with vehicle treatment. As far as we evaluated the cell viability by 
CNSA-MC-183125, Nakamura, et al., page 25
MTS assay, prosultiamine treatment did not affect the viability of total peripheral blood 
CD4+ T cells. These data suggest that prosultiamine in vitro treatment can selectively 
induce apoptosis of HTLV-I-infected cells of the peripheral blood CD4+ T cells of 
HAM/TSP patients.  
     These evidences prompted us to the treatment with prosultiamine against 
HAM/TSP patients because this agent is frequently and easily available as the regimen 
of vitamin B1 deficiency with the safty in Japan. We treated 5 HAM/TSP patients with 
intravenous administration of prosultiamine at the dosages of 40 mg daily for 14 days. 
We showed the profiles of the patients in Table 3. As shown in Table 3, although motor 
disability grade was not changed among 4 of 5 HAM/TSP patients (case 1-4), some 
clinical improvements, such as the reduction of spasticity etc., were individually 
observed. On the other hand, case 5, who had the short duration of illness, showed 
marked improvement of motor function such as the change of motor disability grade 
(Table 3). No adverse events were observed. As far as we monitored the copy numbers 
of HTLV-I provirus in the peripheral blood mononuclear cells before treatment (day 0), 
during treatment (day 7 and 14), and 7 days after treatment (day 21), copy numbers of 
HTLV-I provirus decreased to 33-55 % of them at day 0 at nadir in all HAM/TSP 
patients (Fig. (7b)).  
Overall, our results indicated that prosultiamine treatment against HAM/TSP 
patients have the potential to be able to induce the clinical improvement based on the 
decrease of HTLV-I-infected cells by apoptosis in the peripheral blood, suggesting that 
prosultiamine can work as the new anti-viral agent against HTLV-I. 
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Conclusion 
Since the discovery of HAM/TSP, over 20 years have passed. During that period, 
numerous findings have been presented in the research field of HAM/TSP. 
Unfortunately, these findings have not translated into an optimal therapeutic strategy 
against HAM/TSP. Although the pathphysiology of HAM/TSP is, in a word, a chronic 
inflammatory status triggered by HTLV-I infection, we should treat HAM/TSP as one of 
the infectious diseases because HTLV-I-infected cells are the first responders in the 
development of HAM/TSP. Therefore, the therapeutic strategy that manages to decrease 
or eliminate HTLV-I-infected cells seems to be critical in considering the ideal 
treatment for HAM/TSP. With this regard, either VPA or prosultiamine might function 
as a new anti-viral agent against HTLV-I. However, the trial for the targeting of 
HTLV-I-infected cells toward the depletion of HTLV-I, as a new therapeutic strategy 
against HAM/TSP, has just opened now. 
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Figure legends 
Fig. 1. The immunopathogenesis of and the therapeutic strategies in HAM/TSP. The 
bystander mechanism, such as the destruction of the surrounding tissues by 
inflammatory cytokines expression, etc., during the interaction between 
HTLV-I-infected CD4+ T cells and HTLV-I-specific CD8+ CTL, plays an important role 
as the cause of chronic myelitis in the spinal cord. The therapeutic strategies in 
HAM/TSP are divided to two ways of the direction as shown by    ; 1) 
immunomodulation therapy, such as a) the suppression of immune activation, 
particularly for activated HTLV-I-infected cells, b) the inhibition of the transmigration 
of activated HTLV-I-infected cells to the spinal cord, c) the reduction of chronic 
inflammation in the spinal cord  2) anti-viral therapy, such as a) the suppression of 
HTLV-I expression and/or replication, b) the inhibition of the proliferation of 
HTLV-I-infected cells, c) the elimination of HTLV-I-infected cells.  
 
Fig. 2. The structure of allicin (a) and the generation of prosultiamine (b). Allithiamine 
was originally synthesized by thiol type vitamin B1 and allicin. Prosultiamine was 
developed after allyl disulfide derived from allicin was substituted to propyl disulfide in 
the structure of allithiamine as shown by     . Either prosultiamine or allicin have a 
disulfide moiety in its structure as shown by     . 
 
Fig.3. The cytotoxic effect of allicin or prosultiamine against HTLV-I-infected T cell 
lines derived from HAM/TSP patients (HCT-1 and HCT-4) or non-infected T 
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cell line (Jurkat). a) Cell viability of all cell lines decreased by the treatment with  
allicin for 24 hr in dose-dependent manner. b) Prosultiamine treatment against these cell  
lines also caused the similar effect to allicin treatment. Both HCT-1 and HCT-4 were  
more sensitive for the treatment with each compound than Jurkat cell line.  
HCT-1;      , HCT-4;    , Jurkat;       . For cell viability assay, MTS assay was  
performed. Cell viability was determined as follows: after each OD titer at wavelength  
of 490 nm in triplicate cultures in the presence of allicin, or prosultiamine or vehicle /  
mean of OD titer at wavelength of 490 nm in triplicate cultures under medium alone  
was calculated, its mean + SD was presented as the cell viability.  
 
Fig. 4. The cytotoxic effect of prosultiamine is based on caspase-dependent apoptosis. 
a) The loss of mitochondrial membrane potential and the frequency of annexin 
V-positive cells in prosultiamine-treated HCT-1. After HCT-1 was cultured for 24 hr in 
the presence of 40 M prosultiamine or vehicle, these cells was analyzed by staining the 
cells with the potential sensitive fluorescent dye DiOC6(3) or FITC-conjugated annexin 
V to evaluate m or the frequency of apoptotic cells, respectively. Either the loss of 
m or the frequency of apoptotic cells was measured by flow cytometry. b) The 
recovery of the loss of mitochondrial membrane potential in prosultiamine treatment 
against HCT-1pretreated with z-VAD-fmk. Before the treatment with 40 M 
prosultiamine for 24 hr, HCT-1 was pretreated by 200 M z-VAD-fmk for 1 hr. c) 
Immunoblot analysis of 40 M prosultiamine-treated HCT-1 for the proteolytic 
cleavage of caspase 3. After HCT-1 was cultured for 1, 3, or 5 hr in the presence of 40 
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M prosultiamine, the cells were collected and lysed for immunoblot analysis. The 
treatment of HCT-1 with prosultiamine resulted in the proteolytic cleavage of caspase 3. 
 
Fig. 5. Hypothetical pathway in allicin or prosultiamine-induced apoptosis of 
HTLV-I-infected cells. Trx has two redox-active cysteine residues in an active center 
(-Cys-Gly-Pro-Cys-) and operates together with NADPH and Trx reductase as a protein 
disulfide-reducing system. Trx is a redox-sensitive physiological inhibitor of ASK1 
activity. Reduced form of Trx binds to ASK1 and inhibits kinase activity of ASK1. 
Upon the change to oxidized form of Trx such as formation of disulfides through the 
oxidation of cysteine residues, ASK1 dissociates from Trx and a free ASK1 is 
autophosphorylated in Threonine residue, subsequently activates the cascade of 
apoptosis signaling through p38 MAPK and JNK activation. Both allicin and 
prosultiamine might have the potentials to oxidize Trx in the interaction between 
Trx/Trx reductase system and a disulfide moiety in their structures and induce ASK1 
activation leading to the induction of apoptosis of HTLV-I-infected cells through 
mitochondrial pathway. Trx; Thioredoxin, ASK1; Apoptosis signal-regulating kinase1, 
p38 MAPK/JNK; p38 mitogen-activated protein kinase/c-Jun N-terminal kinase. 
 
Fig. 6. Immunoblot analysis of 40 M prosultiamine-treated HCT-1 for ASK1 
activation. After HCT-1 was cultured for 1, 5, 15, or 30 min in the presence of 40 M 
prosultiamine, the cells were collected and lysed for immunoblot analysis. The 
treatment of HCT-1 with prosultiamine resulted in phosphorylation of ASK1. P-ASK1; 
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phosphorylated ASK1. 
 
Fig. 7. The effect of in vitro and in vivo treatment with prosultiamine for the reduction 
of HTLV-I-infected cells. a) The decrease of numbers of HTLV-I provirus in peripheral 
blood CD4+ T cells of HAM/TSP patients by the in vitro treatment with prosultiamine. 
The peripheral blood CD4+ T cells of HAM/TSP patients were cultured in the presence 
of 5 M prosultiamine or vehicle for 48 hr. After the dead cells induced by 
prosultiamine in vitro treatment were removed using annexin V microbead kit, total 
cellular DNA samples prepared from viable cells were subjected to the measurement of 
HTLV-I proviral copies by quantitative PCR analysis. Prosultiamine treatment induced 
the decrease of HTLV-I proviral copies, ranged from 29.9 - 80.2% (mean; 60.7%) (p < 
0.05), compared with vehicle treatment. b) The decrease of numbers of HTLV-I provirus 
in the peripheral blood mononuclear cells of HAM/TSP patients by the in vivo treatment 
with prosultiamine. We treated 5 HAM/TSP patients with intravenous administration of 
prosultiamine at the dosages of 40 mg daily for 14 days. Total cellular DNA samples 
prepared from the peripheral blood mononuclear cells were subjected to the 
measurement of HTLV-I proviral copies by quantitative PCR analysis. As far as we 
monitored the copy numbers of HTLV-I provirus in the peripheral blood before 
treatment (day 0) (Pre), during treatment (day 7 and 14), and 7 days after treatment (day 
21), copy numbers of HTLV-I provirus decreased to 33-55 % of them at day 0 at nadir 
in all HAM/TSP patients.  
The list of abbreviations: 
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HTLV-I; human T lymphotropic virus type I 
HAM/TSP; HTLV-I-associated myelopathy/tropical spastic paraparesis 
CTL; cytotoxic T cells 
PSL; predonisolone 
PTX; pentoxifylline 
IFN-and -; interferon- and -
RT inhibitor; reverse transcriptase inhibitor 
IL-2; interleukin-2 
HDAC inhibitor; histone deacetylase enzyme inhibitor 
VPA; valproate 
Trx; thioredoxin 
Trx reductase; thioredoxin reductase 
GSH; glutathione 
MTS assay; (3-[4,5-dimethylthiazol-2-yl-5]-[3-carboxymethoxyphenyl]-2- 
[4-sulfophenyl]-2H tetrazolium) nonradioactive cell proliferation assay 




CNSA-MC-166870, Nakamura, et al.
                                     Table 1. Therapeutic strategies in HAM/TSP
     1) The therapies focusing on immunomodulatory effects:
               Mainly directed to anti-inflammatory effects;
                  a) the suppression of immune activation, particularly for activated HTLV-I-infected cells
                  b) the inhibition of the transmigration of activated HTLV-I-infected cells to the spinal cord 
                  c) the reduction of chronic inflammation in the spinal cord
     2) The therapies focusing on anti-viral effects:
                  a) the suppression of HTLV-I expression and/or replication
                  b) the inhibition of the proliferation of HTLV-I-infected cells
                  c) the elimination of HTLV-I-infected cells
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          Table 2. Therapeutic trials against HAM/TSP patients
References
1) The therapies focusing on immunomodulatory effects:
a) Corticosteroid hormone [14], [17]
b) Blood purification [18]
c) Pentoxifylline [21], [22], [24]
d) Heparin [29]
e) High dose-intravenous gammaglobulin [31]
f) Intermittent high-dose vitamin C [32]
g) Fosfomycin and Erythromycin [14], [33], [34]
h) Fermented milk drink [37]   
2) The therapies focusing on anti-viral effects:
a) Interferon- and - [43], [44], [49], [51]
b) Reverse transcriptase inhibitors [57], [58], [59], [60]
c) Humanized anti Tac [64]  -
d) Histone deacetylase enzyme inhibitor [69], [70]
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     Table 3. The profiles of patients and the clinical efficacy of prosultiamine treatment
The changes of motor disability score a)          
Case          Age / Gender  Duration of illness
                  (years) Before After
1           58 / female 24 4 4
2 51 / male 13 8 8            
3           52 / male 46 4 4
4           73 / female 13 4 4
5           53 / female 2 4 2
a) Motor disability score was rated from 0 to 10 according to the scale of reference [18]                . 







